歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

休市中 07-03 16:08:15

11.540

+0.250

+2.21%

最高11.780	最低11.340	成交量260.30万
今开11.600	昨收11.290	日振幅3.90%
总市值122.44亿	流通市值122.44亿	总股本10.61亿
成交额3,004万	换手率0.25%	流通股本10.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":11.54,"timestamp":1783066095004,"preClose":11.29,"halted":0,"volume":2602979,"delay":0,"changeRate":0.022143489813994686,"floatShares":1061000000,"shares":1061000000,"eps":-0.42789047264169444,"marketStatus":"休市中","change":0.25,"latestTime":"07-03 16:08:15","open":11.6,"high":11.78,"low":11.34,"amount":30040070,"amplitude":0.038973,"askPrice":11.54,"askSize":1000,"bidPrice":11.53,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.4335555991370857,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":7,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":11.29,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":1.0049832591914427,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1122570185","title":"歌礼制药-B更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1122570185","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122570185?lang=zh_cn&edition=full","pubTime":"2026-07-03 12:38","pubTimestamp":1783053537,"startTime":"0","endTime":"0","summary":"7月3日，歌礼制药有限公司发布截至2026年6月30日的股份变动月报表。公告显示，公司法定/注册股本维持在7,000,000,000股，每股面值为美元0.0001，对应法定/注册股本总额700,000美元；与上月末保持一致。公司当月并无新增股份期权行使，无库藏股转让活动。公司董事会确认，截至2026年6月30日，相关公众持股量符合适用的最低公众持股量要求。公告由公司秘书钟明辉签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01956","00376","02632","01672","03310","02729","03887","01609","07630","02726","01440","00412","02142","03388","02272","02616","01392","02526","06938","00600","01866","02672","07688","06106","09637","07666","02723","01236","03625","01651","01286","06658","02553","00068","02335","03355","06872","00340","00863","01021","02696","01133","06656","01081","06636","01879","09630","06675","03661","02670","01511","BK4585","01779","00100","01191","BK4588","03277"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1102098626","title":"歌礼制药-B：6月30日回购14.50万股，耗资约152.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102098626","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102098626?lang=zh_cn&edition=full","pubTime":"2026-06-30 18:02","pubTimestamp":1782813771,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司（股票名称：歌礼制药-B，股票代码：01672）于2026年6月30日公告披露，已于香港联合交易所场内回购约14.50万股普通股，占该事件前公司已发行股本约0.0137%。回购价介乎每股10.35港元至10.51港元，合计耗资约152.12万港元。\n本次回购完成后，公司已发行股本为1,061,370,845股，库藏股数为7,084,210股，总股本为1,068,455,055股。该项回购基于2026年6月29日获得股东大会通过的购回授权，公司可回购股份总数为106,137,084股。截至公告日，公司确认已遵守香港联合交易所证券上市规则及相关法例。本次公告由公司秘书钟明辉签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B：6月30日回购14.50万股，耗资约152.12万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534109","title":"歌礼制药-B(01672.HK)6月30日斥资约152.12万港元回购14.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647534109?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:59","pubTimestamp":1782813556,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01477","BK1191","BK1161","01672","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647858653","title":"港股异动 | 歌礼制药-B(01672.HK)再涨近3% 拟使用最多3亿港元资金进行建议股份购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2647858653","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647858653?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:48","pubTimestamp":1782784114,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","01477","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180222986","title":"港股开盘 | 恒指低开0.08%，科指高开0.54%，百度涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180222986","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180222986?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:21","pubTimestamp":1782782497,"startTime":"0","endTime":"0","summary":"6月30日，港股开盘分化，恒生指数跌0.08%，报23007.87点；恒生科技指数涨0.54%，报4416.68点。\n科指成分股表现较强，百度集团涨近6%，小鹏集团涨超4%，MINIMAX-WP上涨1.5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["82800","01672","09067","HSTECH","513600","00100","02800","00285","03033","VXUS","06715","09888","07200","03115","03067","83115","03952","07552","07500","07300","09999","03037","03423","03032","BK4585","HSI","02837","07226","09868","03088","09088","09115","BK4588","02833","03419","03417","07709"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647585166","title":"歌礼制药-B拟回购不超3亿港元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2647585166","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647585166?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:14","pubTimestamp":1782782040,"startTime":"0","endTime":"0","summary":"6月30日，歌礼制药-B（01672）发布公告，董事会决定根据股东于2026年6月29日举行的股东周年大会上授予的回购授权，在合适时间于公开市场上回购股份。根据回购授权，公司获准回购最多1.06亿股股份，相当于股东周年大会日期已发行股份总数的10%。公司计划使用最多3亿元港元的资金进行回购，资金将来自公司内部财务资源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303787525342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","BK1574","BK1191","01672","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647993325","title":"港股异动 | 歌礼制药-B(01672)涨超7% ASC35的I期研究IND获FDA批准 公司年内获GIC连续增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2647993325","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647993325?lang=zh_cn&edition=full","pubTime":"2026-06-29 14:15","pubTimestamp":1782713723,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B涨超7%，截至发稿，涨7.2%，报10.42港元，成交额1323.68万港元。消息面上，歌礼制药-B发布公告，近期已获得美国食品药品监督管理局对其ASC35的I期研究的新药临床试验批准。体外实验显示，ASC35对GLP-1R和GIPR的激动活性比替尔泊肽强约4倍。增持后最新持股数目为8935.30万股，持股比例为8.36%。据悉，本次增持为GIC年内第三次披露对歌礼制药的权益变动，此前两次增持分别于今年2月及5月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1515","LABU","BK1161","BK1574","BK1191","BK4585","IND","GIC","01477","BK4588","VXUS","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646352998","title":"GIC Private Limited增持歌礼制药-B(01672.HK)479.7万股 每股作价约9.98港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646352998","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646352998?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:44","pubTimestamp":1782474242,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","01672","01477","BK1191","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180471794","title":"歌礼制药-B：2026年6月26日回购20万股，耗资约192.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180471794","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180471794?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:26","pubTimestamp":1782469590,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年6月26日发布公告，披露其当日在香港联交所场内进行了股份回购。根据公告，公司当日回购普通股200,000股，约占相关事件前已发行股本的0.0188%。回购价介乎每股9.38港元至9.94港元，涉资总额为港币1,928,830。公告显示，截至2026年6月26日，公司已发行股本为1,061,370,845股，库藏股数量为7,084,210股，总股本合计1,068,455,055股。回购授权决议于2025年5月22日获通过，允许公司回购合计96,284,628股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：2026年6月26日回购20万股，耗资约192.88万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646035676","title":"歌礼制药-B(01672.HK)6月26日斥资192.88万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646035676","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646035676?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:23","pubTimestamp":1782469400,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01477","BK1191","BK1515","01672","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196694951","title":"歌礼制药-B(01672)：2026年6月25日回购20万股，涉资约196.40万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196694951","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196694951?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:42","pubTimestamp":1782380540,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年6月25日刊发翌日披露报表。公告指，公司当日于香港联交所场内回购普通股200,000股，约占公司已发行股本的0.0188%，回购价格介乎每股9.43港元至9.99港元，合计支付1,963,970港元，折合约196.40万港元。公司购回股份授权获通过日期为2025年5月22日，截至本次回购，已于另一家证券交易所及香港联交所合共购回9,686,000股，占购回授权通过当日已发行股本约1.0051%。公告同时披露，公司确认本次股份回购已遵守香港联交所证券上市规则及相关法例。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B(01672)：2026年6月25日回购20万股，涉资约196.40万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646876699","title":"歌礼制药-B(01672.HK)6月25日斥资196.4万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646876699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646876699?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:32","pubTimestamp":1782379924,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01477","01672","BK1574","BK1191","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162794261","title":"歌礼制药-B：6月24日回购20.00万股，耗资约201.81万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162794261","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162794261?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:16","pubTimestamp":1782292590,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年6月24日公告，已在香港联交所场内回购普通股20.00万股，约占公司已发行股本的0.0188%。回购价介乎每股9.97港元至10.25港元；此次交易涉资约201.81万港元。回购完成后，公司已发行股本仍为1,061,370,845股，库存股数维持7,084,210股。从公告可见，此次回购依据2025年5月22日获批的购回授权进行，授权可回购股份总数为96,284,628股，至今累计在包括香港联交所在内的证券交易所回购9,486,000股，占购回授权通过当日已发行股份总数的0.9844%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：6月24日回购20.00万股，耗资约201.81万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645896917","title":"歌礼制药-B(01672)6月24日斥资201.81万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645896917","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645896917?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:12","pubTimestamp":1782292374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月24日斥资201.81万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","BK1574","BK1161","01672","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146063254","title":"歌礼制药宣布其用于治疗肥胖症的月度皮下注射GLP-1R/GIPR双肽激动剂ASC35获美国FDA批准进行I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1146063254","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146063254?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:10","pubTimestamp":1782209436,"startTime":"0","endTime":"0","summary":"歌礼制药宣布，其用于治疗肥胖症的月度皮下注射GLP-1R/GIPR双肽激动剂ASC35，已获得美国食品药品监督管理局的临床试验申请批准，将进入I期研究阶段。该候选药物ASC35是一种创新的长效双激动剂，旨在同时靶向胰高血糖素样肽-1受体和葡萄糖依赖性促胰岛素多肽受体。与目前市场上常见的每日或每周给药方案不同，ASC35采用了每月一次的皮下注射给药方式，有望为患者提供更便捷的治疗选择，并可能改善用药依从性。此次IND获批标志着该药物研发进程中的一个重要里程碑，公司计划尽快启动相关的临床研究以评估其安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01672","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645872788","title":"歌礼制药-B(01672)宣布其每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽ASC35治疗肥胖症的I期研究IND获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645872788","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645872788?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:04","pubTimestamp":1782209049,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 公布，近期已获得美国食品药品监督管理局对其ASC35的I期研究的新药临床试验批准。ASC35是一款有望成为同类最佳、每月一次皮下注射的GLP-1受体/GIP受体 双靶点激动剂多肽，用于治疗肥胖症。体外实验显示，ASC35对GLP-1R和GIPR的激动活性比替尔泊肽强约4倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4588","01672","BK1161","LABU","01477","BK4144","IND","GIPR","GLP","BK4585","BK1191","BK1515","BK4590","BK4160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182230938","title":"歌礼制药-B：2026年6月23日回购20.00万股，耗资约197.70万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182230938","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182230938?lang=zh_cn&edition=full","pubTime":"2026-06-23 17:16","pubTimestamp":1782206190,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年6月23日发布公告称，公司在香港联交所场内回购普通股20.00万股，约占当日已发行股本的0.0188%。此次回购每股价格介乎9.67港元至10.07港元，成交量加权平均价9.88港元，合计耗资约197.70万港元。公告显示，截至2026年6月23日，公司已发行股本为1,061,370,845股，库藏股为7,084,210股，总股本为1,068,455,055股。由于此次所回购的股份尚未注销，股本总数暂未发生变化。截至目前，公司已累计回购股份9,286,000股，占购回授权通过当日已发行股本总数约0.9636%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：2026年6月23日回购20.00万股，耗资约197.70万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106671231","title":"歌礼制药-B：6月22日回购20万股，总额约190.10万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106671231","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106671231?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:06","pubTimestamp":1782122796,"startTime":"0","endTime":"0","summary":"歌礼制药-B6月22日发布翌日披露报表，公告当日于香港联交所场内回购普通股20万股，约占该公司已发行股本的0.0188%。每股回购价介乎每股9.25港元至9.74港元，合计涉资约190.10万港元。根据公司2025年5月22日通过的购回授权，剩余可回购股份数量为9628.46万股，公司已累计回购约908.6万股，占购回授权通过当日已发行股本约0.9429%。公司确认此次回购活动严格遵守香港联交所上市规则及适用法例规定。公告由公司秘书钟明辉签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：6月22日回购20万股，总额约190.10万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645002593","title":"歌礼制药-B(01672)6月22日斥资190.1万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645002593","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645002593?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:05","pubTimestamp":1782122704,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月22日，该公司斥资190.1万港元回购20万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","01672","BK1574","BK1191","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.1872},{"period":"1month","weight":0.161},{"period":"3month","weight":-0.3204},{"period":"6month","weight":0.0017},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0132}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0891},{"period":"3month","weight":-0.0703},{"period":"6month","weight":-0.1135},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.053675},{"month":7,"riseRate":0.625,"avgChangeRate":0.039742},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}